Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bafna PharmaceuticalsNSE:BAFNAPH -2.00%58 Days Sales Outstanding is 150.79 as of Jun. 2026, which is 43% above its 10-year median of 105.33. GuruFocus rates NSE:BAFNAPH with a GF Score™ of 58/100 and a GF Value™ of ₹85.89 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 947 Drug Manufacturers companies, Bafna Pharmaceuticals ranks worse than 72.12% on this metric.
The historical rank and industry rank for Bafna Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:
NSE:BAFNAPH'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.96 Med: 105.33 Max: 342.01
Current: 99.56
During the past 13 years, Bafna Pharmaceuticals's highest Days Sales Outstanding was 342.01. The lowest was 39.96. And the median was 105.33.
NSE:BAFNAPH's Days Sales Outstanding is ranked worse than 72.12% of 947
companies
in the Drug Manufacturers industry
Industry Median: 71.98
vs NSE:BAFNAPH: 99.56
Bafna Pharmaceuticals's Days Sales Outstanding
increased
from Jun. 2025 (105.88) to Jun. 2026 (150.79).
Bafna Pharmaceuticals (NSE:BAFNAPH) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Bafna Pharmaceuticals Days Sales Outstanding Related Terms
Bafna Pharmaceuticals Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Bafna Pharmaceuticals's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bafna Pharmaceuticals Days Sales Outstanding Chart
NSE:BAFNAPH vs ZTS: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bafna Pharmaceuticals Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Bafna Pharmaceuticals's Days Sales Outstanding falls into.
Bafna Pharmaceuticals Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 150.79 mean?
Bafna Pharmaceuticals (NSE:BAFNAPH) has a Days Sales Outstanding of 150.79 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Bafna Pharmaceuticals and its competitors. This is 43% above median its historical median of 105.33. Over the past decade, Bafna Pharmaceuticals' Days Sales Outstanding has ranged from 39.96 to 342.01. According to the industry distribution chart, Bafna Pharmaceuticals ranks #683 out of 947 companies in the Drug Manufacturers industry, placing it in the top 72.1%.
Is Bafna Pharmaceuticals' Days Sales Outstanding too high?
Bafna Pharmaceuticals' current Days Sales Outstanding of 150.79 is 43% above median its 10-year median of 105.33. Over the past 10 years, this metric has ranged from a low of 39.96 to a high of 342.01. The Drug Manufacturers industry median Days Sales Outstanding is 71.98. Bafna Pharmaceuticals' value of 150.79 is 109.5% above this industry median. Based on the distribution chart, Bafna Pharmaceuticals ranks #683 out of 947 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bafna Pharmaceuticals has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' Days Sales Outstanding compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bafna Pharmaceuticals ranks #683 out of 947 companies for Days Sales Outstanding. This places Bafna Pharmaceuticals in the lower half of its industry. The industry median Days Sales Outstanding is 71.98. Bafna Pharmaceuticals' value of 150.79 is 109.5% above this benchmark. Historically, Bafna Pharmaceuticals' own Days Sales Outstanding has ranged from 39.96 to 342.01 over the past decade. While the company's 10-year median is 105.33 vs. the industry median of 71.98, Bafna Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.98, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bafna Pharmaceuticals's current Days Sales Outstanding of 150.79 is 109.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Bafna Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bafna Pharmaceuticals's current Days Sales Outstanding is 150.79, which is 43% above median its own 10-year median of 105.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹85.89, compared to a current price of ₹301.45 — trading 251% above its estimated fair value. The current Days Sales Outstanding is 150.79, which is 43% above median its 10-year median of 105.33 and 109.5% above the Drug Manufacturers industry median of 71.98. Bafna Pharmaceuticals' overall GF Score™ is 58/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current Days Sales Outstanding is 150.79 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?
Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹301.45 is trading 251% above its estimated GF Value™ of ₹85.89.
GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:BAFNAPH:
Days Sales Outstanding: 150.79 (43% above median its 10-year median of 105.33)
GF Value™: ₹85.89 vs. price of ₹301.45 (251% above fair value)
Industry Position: 109.5% above the Drug Manufacturers median (#683 of 947)
No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
58GF Score
Get the complete analysis for NSE:BAFNAPH
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BAFNAPH has been successfully added to your 
